Previous 10 | Next 10 |
Summary We initiate Xenon Pharmaceuticals with a BUY rating. We see XENE as one of the most de-risked and compelling SMID-cap biotech companies with a lead late-stage clinical candidate. We build a high degree of conviction based on recent phase 2b X-TOLE data that demonstrated a si...
Summary Omeros Corporation's stock has rallied 66% on Feb 6th based on the milestone payment of $200M, which eliminated the potential cash runway overhang some investors were worried about. With the additional $200M cash, now the enterprise value of the company is around $115M, which we...
Summary The Fed changed its communication strategy, which was misinterpreted as bullish. The Fed acknowledged the alternative outlooks as possible. However, the bets against the Fed's outlooks are likely to be burned by the incoming data. The bear market in SPY likely to continu...
Summary Verona Pharma is a UK-based biotech with a $1.6Bn market cap developing a phase 3 asset targeting COPD. Ensifentrine is a novel phase 3 inhaled selective dual inhibitor of PDE3 and PDE4 targeting COPD, which is a $10Bn indication with a high unmet need. Verona Pharma has a s...
Summary Dividend Aristocrats have underperformed in 2023 after a stellar year relative to the S&P 500. With an earnings date ahead, shares appear reasonably priced while the chart shows a potential trend change. I outline key price levels to watch on this turnaround name. ...
Summary The Health Care sector has been a big loser in 2023 after last year's relative rally. Baxter International follows up some disappointing results from other sector names. With a strong EPS beat rate history, but terrible share price reaction trend, shares could dip, but are n...
Summary We initiated KemPharm with a Sell rating in March 2021; since then, the stock has declined >40%, and now the stock is trading at an attractive enterprise value of $130m. AZSTARYS targeting ADHD has been approved, and it no longer contributes much to the stock price at this po...
Making money in the stock market doesn't have to be complicated; the biggest obstacles to earning a great return often involve investors themselves. Getting caught up in the latest meme hype, taking on too much risk, or simply lacking patience are some of the biggest reasons investors don't achie...
Summary The Health Care Select Sector SPDR was a safe haven in 2022. XLV has also outperformed over the longer term. Demographic trends make reining in U.S. health care expenditures unlikely. The market-implied outlook (calculated using options on XLV) continues to be bullish. ...
Summary MorphoSys AG is a German commercial-stage biopharmaceutical company founded in 1992 with more than 100+ pipeline candidates. We believe MorphoSys's two key value drivers are a) monjuvi and b) pelabresib. We expect Monjuvi's sales to continue to falter. There are no short...
News, Short Squeeze, Breakout and More Instantly...
SPDR Select Sector Fund - Health Care Company Name:
XLV Stock Symbol:
NYSE Market:
2024-07-09 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-29 11:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-09 09:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...